The present invention relates to a transgenic mouse whose genome is heterozygous for a disruption of a native Elovl4 gene. The transgenic mouse and cells derived therefrom can be used to screen drug or food supplement for the treatment and prevention of visual disorders such as Stargardt-like dominant macular dystrophy.